ARE YOU A COMMUNITY MEDICAL OR RADIATION ONCOLOGIST?
- Interested In Starting A Radiopharmaceutical Program At Your Center But Seems Complex?
- Interested In Conducting Radiopharmaceutical Clinical Trials But Have No Current Or Limited Clinical Trials Program
- Interested In Helping Fill The Critical Shortage Of Community Cancer Centers Capable Of Conducting Radiopharmaceutical Clinical Trials
XCancer® has the experts and the experience to provide your center with the backbone, tools, strategies, and business models to make you successful at both. XCancer® is a community cancer center with a solo medical oncologist that has developed a leading radiopharmaceutical clinical trials program recognized globally. Using its experience and processes, XCancer® has successfully guided community cancer centers across the United States with developing highly efficient and quality clinical trial programs.
Start your program today:
Physicians
Advanced Knowledge & Opportunites
- Advance your Knowledge of Theranostics, Radiation, & Clinical Trials
- Search a Comprehensive List of Global Oncology-Theranostic clinical trials
- Easy access to Publications & Presentations regarding investigational Theranostic agents
- Opportunities & Access to Strategy Advisors on How to Develop a Theranostic Clinical Trials Program at Your Site
- Access to Clinical Trials Sponsors in search of potential clinical trial sites
- Keep updated of Upcoming Theranostic Conferences
Distinguished Investigator
A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
RLT Components
RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.
There are several Components to a RLT that are simply demonstrated in the truck diagram including:
- Cancer Targets
- Ligand (demonstrated as the Truck GPS set to find a specific Target)
- Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
- Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
- Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
- Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).
To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.
Education
Stats
Conferences
High Country Nuclear Medicine Conference
High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking.PEGS Boston
Radiopharmaceutical therapies are a rapidly advancing approach in medicine that leverages the unique properties of radioactive isotopes to selectively target and treat various diseases, particularly cancers. These targeted therapies have shown promising results in the treatment of a variety of solid tumors and hematological malignancies, including prostate cancer, neuroendocrine tumors, lymphoma, and select forms of leukemia. As the field continues to advance, researchers are exploring new targeting strategies, novel radioisotope applications, and personalized treatment approaches to further improve patient outcomes. We are inviting leading experts to share their case studies and showcase the tremendous potential of radiopharmaceutical therapies to transform patient care.35th Annual European Pharma Congress
The main theme of the conference is “Discover the Future : The Next Era of Pharma Awaits”. This strategic congress will offer speakers the opportunity to network with like-minded experts while discussing how to address the challenges confronting pharmaceutical product development and synthesis today. It features keynote presentations, oral presentations, poster presentations, symposia, workshops, exhibitions, and career development sessions.Targeted Radioligand Therapies
Cambridge Healthtech Institute's Inaugural event will explore the latest advancements, challenges, and opportunities in this rapidly evolving field, fostering collaborations among researchers, clinicians, and industry leaders to drive the development of these innovative treatmentsDubai Radiotheranostics Summit
Radiotheranostics, radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. The Dubai Radiotheranostics Summit aims to raise awareness, as well as address challenges and opportunities around this cancer care approach. By gathering multiple points of view from specialists from the field, we aim to give a broad perspective of how to accelerate the setting-up of the structure to enhance patient access.PDDS 2025
PDDS 2025 will feature a comprehensive program covering a wide array of topics, from the latest developments in drug delivery systems to advances in biotherapeutics and the impact of COVID-19 on the pharmaceutical industry. The event will delve into areas such as cellular targeting, vaccine design, pharmaceutical microbiology, and nanotechnology, ensuring a holistic approach to understanding the challenges and innovations shaping the future of drug delivery. By addressing both the scientific and regulatory aspects of the industry, the conference aims to provide a complete overview of the current landscape and future possibilities.TRP: Target Selection & Drug Design Summit
Diversifying Radiopharmaceutical Pipelines by Characterizing Novel Radiopharmaceutical Targets While Expanding the Drug Design Toolkit with Cutting-Edge Targeting Strategies, Linker & Chelator Technologies & Illuminating Radiobiological MechanismsInternational Conference on Radiopharmacy and Radiopharmaceuticals
International Conference on Radiopharmacy and Radiopharmaceuticals aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Radiopharmacy and Radiopharmaceuticals. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Radiopharmacy and Radiopharmaceuticals.JP Morgan Health Care Conference
The 43rd Annual Healthcare Conference will take place on January 13-16, 2025 in San Francisco, CA. This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Fourth Transatlantic Exchange in Oncology
Leaders from the Dana-Farber Cancer Institute and Gustave Roussy, recognized globally for their expertise, will present on such topics as: Precision Oncology and molecular imaging – early detection; How to go from non-Radio-labeled target to a Radio-labeled active product; Latest clinical applications; and Perspectives from Academia and Industry on Radioligand Therapies. The meeting will be chaired by Professor Toni Choueiri, MD, medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School and Professor Karim Fizazi, Gustave Roussy and Université Paris-Saclay, head of the International Academic Network at Gustave Roussy. The Keynote speaker is Michael Morris, MD, FASCO, Prostate Cancer Section Head, Genitourinary Oncology, Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center (NYC, USA). His keynote presentation will discuss Seeing beyond VISION: Designing Radioligand Therapy trials that yield a survival benefit.PSMA and Beyond
Held by the University of California - San Francisco, with help from sponsorships from UCLA Health, UCSF Health, and the Prostate Cancer FoundationASCO Annual Meeting
ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwideSponsors
.svg)
